Pfizer (PFE)

Financing Cash Flow

-$8.40B

TTM · Period ending: · USD

PFE logo

PFE Financing Cash Flow

Latest reported-$8.40B
PFE TTM Cash from Financing (-$499.90M → -$8.40B)
High-resolution chart · PNG

PFE financing cash flow history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Pfizer Financing Cash Flow — Trailing twelve months (TTM) (USD)
Period endingFinancing Cash Flow (USD)
-8,399,000,000
-7,932,000,000
-10,303,000,000
-16,013,000,000
-18,173,000,000
-17,436,000,000
-17,140,000,000
-6,584,000,000
-5,727,000,000
23,906,000,000
26,066,000,000
15,609,000,000
13,627,000,000
-11,027,000,000
-14,834,000,000
-13,170,000,000
-8,510,000,000
-13,587,000,000
-9,816,000,000
-20,252,000,000
-21,972,000,000
-10,256,000,000
-9,649,000,000
1,698,000,000
7,792,000,000
-2,218,000,000
-8,485,000,000
-12,452,000,000
-17,131,000,000
-18,188,000,000
-20,441,000,000
-17,419,000,000
-17,741,000,000
-18,834,000,000
-13,035,000,000
-11,878,000,000
-11,774,000,000
-6,828,000,000
-8,921,000,000
-7,802,000,000
-6,445,000,000
-10,265,000,000
-10,233,000,000
-12,050,000,000
-14,670,000,000
-14,835,000,000
-9,986,000,000
-12,804,000,000
-15,548,000,000
-17,542,000,000
-14,975,000,000
-15,464,000,000
-13,124,000,000
-12,058,000,000
-15,999,000,000
-16,016,000,000
-16,760,000,000
-17,710,000,000
-20,607,000,000
-15,436,000,000
-13,924,000,000
-14,367,000,000
-11,174,000,000
-12,829,000,000
-12,134,000,000
1,635,000,000
14,481,000,000
14,962,000,000
14,412,000,000
2,227,000,000
-6,560,000,000
-4,507,000,000
-6,381,000,000
-6,914,000,000
-12,610,000,000
-16,664,000,000
-17,515,000,000
-19,182,000,000
-23,100,000,000
-14,520,000,000
-11,279,000,000
-17,170,000,000
-9,222,000,000
-16,897,000,000
-19,031,000,000
-9,030,000,000
-6,629,000,000
-8,665,000,000
-8,225,000,000
-15,074,000,000
-16,909,000,000
-14,568,000,000
-11,951,000,000
-5,041,000,000
-4,999,000,000
-3,237,000,000
-2,847,000,000
-1,832,000,000
-2,096,000,000
-3,315,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.